A Fortunate Eruption of Malignancies: Nivolumab-Induced Squamous Cell Carcinomas

© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

Conflict of interest

None declared.

References

1. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017;41:125–8.
2. Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 2019;33:1–12.
3. Poole M, Schwartz RA, Lambert WC, Alhatem A. To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma. Arch Dermatol Res 2023;315:903–15.
4. Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, Multicenter, phase II trial. Ann Oncol 2021;32:1276–85.
5. Fradet M, Sibaud V, Tournier E, Lamant L, Boulinguez S, Brun A, et al. Multiple keratoacanthoma-like lesions in a patient treated with pembrolizumab. Acta Derm Venereol 2019;99:1201–302.
6. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015;151:1206–12.

Previous article in this issue

Next article in this issue

Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing